This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
HealthEquity (HQY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity Inc (HQY) reported earnings of 19 cents per share in the first quarter of fiscal 2018, higher than the Zacks Consensus Estimate of 16 cents.
Amedisys (AMED) Prospects Impressive Amid Tough Competition
by Zacks Equity Research
On Jun 5, we issued an updated research report on leading molecular diagnostic company, Amedisys, Inc. (AMED).
Abiomed (ABMD) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Abiomed, Inc. (ABMD), scaled a new 52-week high of $142.95 on Jun 5, eventually closing a bit lower at $141.81.
Edwards Lifesciences (EW) SAPIEN 3 THV Gets FDA Approval
by Zacks Equity Research
Edwards Lifesciences Corporation (EW) recently announced the receipt of FDA approval for aortic and mitral valve-in-valve procedures using SAPIEN 3 transcatheter heart valve (THV).
Tenet Healthcare Prices New Notes to Repay Existing Debts
by Zacks Equity Research
Tenet Healthcare Corporation (THC) recently priced the previously announced private offering of newly issued notes.
QIAGEN Strengthens Cancer Research Foothold on New License
by Zacks Equity Research
QIAGEN N.V. (QGEN) has received a worldwide license for biomarkers to be used in identifying patients who may have benefited from immune-oncology (I-O) therapies in cancer treatment.
Myriad Genetics BRACAnalysis CDx in OlympiAD Results Positive
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN), a leading molecular diagnostics and personalized medicine company recently unveiled positive data pertaining to its BRACAnalysis CDx test.
Align Sets Up Manufacturing Center in China, Grows in APAC
by Zacks Equity Research
Align Technology (ALGN) has recently inaugurated a new Invisalign treatment planning facility in Chengdu, China.
Abbott Laboratories at 52-Week High on Product Line, Buyouts
by Zacks Equity Research
Share price of IL-based Abbott Laboratories (ABT) scaled a new 52-week high of $46.55 on Jun 2, eventually closing a bit lower at $46.50.
QIAGEN & Bristol-Myers Squibb Partner on Cancer Research
by Zacks Equity Research
QIAGEN N.V. (QGEN) has made significant advancement in the field of cancer research through the use of its revolutionary next-generation sequencing (NGS) technology.
Five Stocks Rocketing Higher on Huge Momentum
by David Bartosiak
The bears were sent running, screaming towards their caves today as the market started strong and didn???t look back at all
Align Technology Upgrades iTero Element Intraoral Scanners
by Zacks Equity Research
Based in California, leading dental product maker Align Technology, Inc. (ALGN) recently announced a software upgrade to its iTero Element intraoral scanners.
UnitedHealth Unit Taps Connecticut Orthopedic Surgery Market
by Zacks Equity Research
Surgical Care Affiliates, Inc, a part of UnitedHealth Group's Optum unit, recently partnered with Western Connecticut Orthopedic Surgery Center by making an equity investment in the latter.
Why WellCare (WCG) Stock Should Be in Your Portfolio Now
by Zacks Equity Research
Leading managed care company WellCare Health Plans, Inc.'s (WCG) business strategies should continue to support growth.
Align Technology Rises with Invisalign, SmartTrack Patents
by Zacks Equity Research
Align Technology (ALGN) has received two U.S. Patents from the United States Patent and Trademark Office (USPTO) for its SmartTrack clear aligner material.
Quest Diagnostics Poised on Solid Q1 Results Despite Woes
by Zacks Equity Research
On May 22, we issued an updated research report on Quest Diagnostics, Inc. (DGX), a major commercial laboratory services provider.
Medtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint
by Zacks Equity Research
Medtronic plc (MDT) recently announced favorable outcome on its Resolute Onyx Drug-Eluting Stent.
Edwards Lifesciences SAPIEN 3 Heart Valve Data Positive
by Zacks Equity Research
Edwards Lifesciences Corporation (EW) recently unveiled positive one-year data on its SAPIEN 3 transcatheter heart valve.
Is the Time Ripe to Invest in Paylocity Holding (PCTY)?
by Zacks Equity Research
If you are planning your portfolio, then Paylocity Holding Corporation (PCTY) can be a wise pick.
Why Align Technology (ALGN) Could Be an Impressive Growth Stock
by Zacks Equity Research
A company that might be well-positioned for future earnings growth is Align Technology, Inc. (ALGN).
Top Stock Picks for the Week of May 8th
by Panel Of Zacks Experts
Two Strong Buys With Two Strong Stories.
Align Technology Invisalign Sales Strong, Currency Woes Stay
by Zacks Equity Research
On May 5, we issued an updated research report on Align Technology (ALGN), which manufactures a system of clear aligner therapy.
Align Technology, Community Health Systems, Ultra Clean Holdings, Tyson Foods and Huntsman highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Align Technology, Community Health Systems, Ultra Clean Holdings, Tyson Foods and Huntsman highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Align Technology (ALGN)
by Kevin Cook
Clearly, investors will continue to smile with this 25% grower in their portfolios
Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene